Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Avidity Biosciences, Inc. (RNA) Receivables - Net (2022 - 2024)

Avidity Biosciences' Receivables - Net history spans 3 years, with the latest figure at $1.6 million for Q1 2024.

  • For Q1 2024, Receivables - Net changed N/A year-over-year to $1.6 million; the TTM value through Mar 2024 reached $1.6 million, changed N/A, while the annual FY2023 figure was $1.1 million, 53.26% down from the prior year.
  • Receivables - Net reached $1.6 million in Q1 2024 per RNA's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $2.4 million in Q4 2022 to a low of $1.1 million in Q4 2023.
  • Average Receivables - Net over 3 years is $1.6 million, with a median of $1.4 million recorded in 2023.
  • The largest YoY upside for Receivables - Net was 53.26% in 2023 against a maximum downside of 53.26% in 2023.
  • A 3-year view of Receivables - Net shows it stood at $2.4 million in 2022, then crashed by 53.26% to $1.1 million in 2023, then soared by 42.53% to $1.6 million in 2024.
  • Per Business Quant, the three most recent readings for RNA's Receivables - Net are $1.6 million (Q1 2024), $1.1 million (Q4 2023), and $1.2 million (Q2 2023).